Abstract
A study was conducted to compare the efficiency and toxicity of two peripheral blood stem cell (PBSC) mobilization procedures for newly diagnosed patients with multiple myeloma. Patients from group 1 (n=51) were treated by high-dose cyclophosphamide (HD-CY) plus G-CSF (5 microg/kg/day), and the second group (n=31) by VAD regimen plus G-CSF administration (10 microg/kg/day). Successful mobilization, defined by a minimal count of 2.5 x 10(6) CD34(+) cells/kg collected, was achieved in 96 and 90% of patients in groups 1 and 2, respectively (P=0.15). The mean peripheral blood CD34(+) cells concentration and the mean CD34(+) cells/kg collected were higher in group 2 than in the group 1 (P=0.05). The mean number of leukaphereses necessary to collect a count of 2.5 x 10(6) CD34(+) cells/kg was reduced in group 2 compared to group 1. Adverse events, blood products consumption and time spent in the hospital were significantly greater after HD-CY. In conclusion, VAD plus a G-CSF dose of 10 microg/kg administration seems preferential to HD-CY plus a G-CSF dose of 5 microg/kg for PBSC collection because of equivalent or better efficiency in stem cell mobilization, strong favorable toxicity profile and reduced cost.
References
Sep 1, 1987·European Journal of Haematology·R CollinF E Preston
May 24, 1984·The New England Journal of Medicine·B BarlogieR Alexanian
Aug 1, 1997·Bone Marrow Transplantation·A AlegreJ M Fernández-Rañada
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K R DesikanG Tricot
Sep 16, 1998·Leukemia·G MaritJ Reiffers
Sep 14, 1999·Bone Marrow Transplantation·F LefrereJ Miclea
Feb 13, 2001·British Journal of Haematology·K R DesikanB Barlogie
Jul 31, 2001·Bone Marrow Transplantation·O FitoussiG Marit
Sep 5, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A K StewartJ Berenson
Mar 14, 2003·Bone Marrow Transplantation·E JantunenK Remes
Dec 4, 2003·Bone Marrow Transplantation·K A LerroD L Cooper
Dec 26, 2003·The New England Journal of Medicine·Michel AttalUNKNOWN InterGroupe Francophone du Myélome
Jul 27, 2004·Bone Marrow Transplantation·M KaranthD W Milligan
Citations
Dec 13, 2012·International Journal of Hematology·Sung-Hoon JungJe-Jung Lee
Jun 26, 2009·Leukemia·S GiraltUNKNOWN IMWG
Oct 31, 2007·Bone Marrow Transplantation·E JantunenK Remes
Jun 14, 2012·Bone Marrow Research·Khalid Ahmed Al-Anazi
Dec 18, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Sibel HacıoğluAli Keskin
Mar 15, 2011·Advances in Therapy·François LefrèreMarina Cavazzana-Calvo
Oct 6, 2007·Leukemia & Lymphoma·Giuseppe MiloneRosario Giustolisi
Feb 2, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christopher ParrishUNKNOWN National Cancer Research Institute Haemato-Oncology Clinical Studies Group
Feb 14, 2012·Clinics in Geriatric Medicine·Anthony MatoAndre Goy
Jan 10, 2008·European Journal of Haematology·Esa Jantunen, Taru Kuittinen
Sep 23, 2014·Acta Clinica Belgica·D SelleslagD Dierickx
Sep 21, 2007·Transfusion·François LefrèreChantal Brouzes
Oct 1, 2011·American Journal of Hematology·Guner Hayri OzsanMorie A Gertz
Aug 3, 2013·American Journal of Hematology·Ivana N MicallefJohn F DiPersio
Oct 22, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sergio GiraltSteven Devine
May 24, 2016·Bone Marrow Transplantation·D J GreenA K Gopal
Sep 8, 2004·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Hao Jing, David D Kitts
Jul 15, 2009·Bone Marrow Transplantation·T OzcelikT Demirer
Jul 20, 2010·British Journal of Haematology·Morie A Gertz